tiprankstipranks
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
US Market
CLRB
Cellectar Biosciences
RESEARCH TOOLSreports
Want to see CLRB full AI Analyst Report?

Cellectar Biosciences (CLRB) Stock News & Sentiment

1,437 Followers
Cellectar Therapeutics: Advancing Targeted Radiotherapeutics with Clear Clinical Catalysts Supporting a Buy Rating and $10 Price Target
Premium
Ratings
Cellectar Therapeutics: Advancing Targeted Radiotherapeutics with Clear Clinical Catalysts Supporting a Buy Rating and $10 Price Target
18d ago
CLRB
Cellectar Biosciences Charts Risky Path to Approvals
Premium
Company Announcements
Cellectar Biosciences Charts Risky Path to Approvals
2M ago
CLRB
CLRB Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
CLRB Upcoming Earnings Report: What to Expect?
2M ago
CLRB
Cellectar Advances CLR 125 Into Early Breast Cancer Trial, Adding Depth to Its Radiotherapy Pipeline
Premium
Company Announcements
Cellectar Advances CLR 125 Into Early Breast Cancer Trial, Adding Depth to Its Radiotherapy Pipeline
4M ago
CLRB
Cellectar Biosciences Reports Q3 2025 Financial Progress
Premium
Company Announcements
Cellectar Biosciences Reports Q3 2025 Financial Progress
6M ago
CLRB
Cellectar Biosciences: Positive Outlook Amidst Challenges
Premium
Company Announcements
Cellectar Biosciences: Positive Outlook Amidst Challenges
6M ago
CLRB
Cellectar Biosciences Inc (CLRB) Q3 Earnings Cheat Sheet
Premium
Pre-Earnings
Cellectar Biosciences Inc (CLRB) Q3 Earnings Cheat Sheet
6M ago
CLRB
More CLRB News >

CLRB News on the Web

Cellectar Therapeutics: Advancing Targeted Radiotherapeutics with Clear Clinical Catalysts Supporting a Buy Rating and $10 Price Target
TipRanks News
Bullish
Cellectar Biosciences enrolls first patient in CLR 121125 trial
TipRanks News
Bullish
Cellectar Biosciences upgraded to Buy from Hold at Maxim
TipRanks News
Bullish
Cellectar Biosciences Charts Risky Path to Approvals
TipRanks News
Neutral
Q4 2025 Cellectar Biosciences Inc Earnings Call Transcript
GuruFocus News
Neutral
Cellectar (CLRB) Q4 2025 Earnings Call Transcript
The Motley Fool
Neutral
Cellectar Biosciences price target lowered to $14 from $18 at Roth Capital
TipRanks News
Neutral
Cellectar Biosciences reports FY25 EPS ($8.35) vs ($41.89) last year
TipRanks News
Neutral

News Score - Last 7 Days

Positive
CLRB
Sector Average
Media Buzz
This Week2 articles
Weekly Average0 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CLRB’s Media Buzz Sentiment?
Currently, no data Available
What is CLRB’s weekly average amount of articles?
Currently, no data Available
What is CLRB’s News Sentiment?
100% of articles about CLRB were positive this week, compared to its sector average of 70%.
    Healthcare Stocks that are Trending in the News
    TVTXTravere Therapeutics
    HVOOpen Orphan Plc
    PBMPsyence Biomedical
    QDELQuidelOrtho
    Showing the stocks with the most bullish news sentiment over the past week